ArticleRheumatology (Oxford, England)2026
The incidence, mortality and complications of systemic lupus erythematosus: a population-level cohort study from 2012 to 2023.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidisciplinary teams in lupus nephritis: where is the evidence for improved outcomes?Clinical kidney journal · 2026Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEthnicity-related inequalities in the epidemiology of systemic lupus erythematosus (SLE) have been consistently described, yet robust population-level data remain limited. We aimed to characterize the incidence, all-cause mortality and complications of SLE in a contemporary, ethnically diverse, nationwide cohort.
methodsWe conducted a population-level study using the Clinical Practice Research Datalink in England. Individuals aged ≥18 years with new SLE diagnoses between 2012 and 2023 were included. Controls were selected in a 4:1 ratio and matched on age, sex and primary care practice. Risk of death and complications were estimated using flexible parametric and competing-risk models, respectively.
resultsThe cohort consisted of 4937 incident SLE diagnoses (87.9% female; median age 47 years). The incidence of SLE declined over the study period across all ethnicities. Compared with controls (n = 19 707), patients with SLE had significantly higher mortality risk [hazard ratio (HR) 2.06; 95% CI: 1.84, 2.32] and elevated risk of all studied complications except solid cancers. SLE incidence was highest among people of Black ethnic background, with the greatest rates observed in Black Caribbean individuals (11.07 per 100 000 person-years in 2023; 95% CI: 6.05, 18.58). Compared with White individuals with SLE, Black individuals had significantly higher mortality (HR 1.64; 95% CI: 1.05, 2.55) and increased risks of diabetes, thrombosis, myocarditis/pericarditis and interstitial lung disease.
conclusionDespite declining incidence, mortality for people with SLE was twice that of controls in this large contemporaneous incident cohort. Ethnicity-based inequalities were observed, with elevated mortality and morbidity risk in Black ethnic groups with SLE compared with White ethnic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.